Massachusetts Wealth Management Has $1.18 Million Holdings in Invesco Biotechnology & Genome ETF $PBE

Massachusetts Wealth Management raised its position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 1.0% in the second quarter, HoldingsChannel.com reports. The firm owned 18,394 shares of the company’s stock after purchasing an additional 190 shares during the quarter. Massachusetts Wealth Management’s holdings in Invesco Biotechnology & Genome ETF were worth $1,179,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PBE. Wealth Enhancement Advisory Services LLC increased its position in Invesco Biotechnology & Genome ETF by 10.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,066 shares of the company’s stock valued at $271,000 after purchasing an additional 390 shares during the period. Farther Finance Advisors LLC grew its position in shares of Invesco Biotechnology & Genome ETF by 256.8% during the 1st quarter. Farther Finance Advisors LLC now owns 8,616 shares of the company’s stock worth $535,000 after buying an additional 6,201 shares during the period. Janney Montgomery Scott LLC grew its position in shares of Invesco Biotechnology & Genome ETF by 12.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 5,424 shares of the company’s stock worth $344,000 after buying an additional 604 shares during the period. Millstone Evans Group LLC grew its position in shares of Invesco Biotechnology & Genome ETF by 75.8% during the 1st quarter. Millstone Evans Group LLC now owns 1,684 shares of the company’s stock worth $107,000 after buying an additional 726 shares during the period. Finally, Banque Cantonale Vaudoise acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the 1st quarter worth approximately $34,000.

Invesco Biotechnology & Genome ETF Stock Up 0.2%

Shares of PBE stock opened at $72.05 on Thursday. The company has a market cap of $226.24 million, a price-to-earnings ratio of 20.44 and a beta of 0.87. Invesco Biotechnology & Genome ETF has a 52 week low of $54.52 and a 52 week high of $73.03. The firm has a 50 day moving average of $68.91 and a 200-day moving average of $64.99.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.